GLPwatch

Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.

Biomedicines · 2024

Last updated 2026-05-28

This review examines how obesity, insulin sensitivity, and treatments like metformin and GLP-1 drugs (such as exenatide, liraglutide, and semaglutide) may affect infertility and polycystic ovary syndrome (PCOS). It notes that current research does not clearly define the specific benefits of GLP-1 drugs for PCOS, and more studies are needed to determine the best doses and treatment lengths for these medications.

AI summary of the abstract below.

JournalBiomedicines, 2024
Citations19
Relative citation ratio7.10
NIH percentile96
Molecules
Conditions studied Pcos, Obesity

Abstract

BACKGROUND: The purpose of this narrative review is to describe the mechanisms that are responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s. METHODS: The relevant publications were identified after systematic queries of the following sources: PubMed, Google Scholar, Web of Science, and publishers' databases, complemented by a cross-check of the reference lists. We used a combination of the search terms "polycystic ovary syndrome", "obesity" and "insulin resistance" with "metformin", "exenatide", "liraglutide", "semaglutide", "orlistat" and terms relevant to the topic of each paragraph (e.g., "pathophysiology", "metabolism", "infertility", "treatment"). RESULTS: All articles describing the mechanisms responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s, were considered for this review. CONCLUSIONS: The existing research on GLP-1 receptor agonists (GLP-1RAs) has not conclusively established a specific therapeutic use for these drugs. Additionally, the efficacy of the newer generation of GLP-1RAs, particularly in terms of dosage and duration of exposure, warrants more extensive research. Understanding the optimal dosing and treatment duration could significantly enhance the therapeutic use of GLP-1RAs in managing PCOS and its associated conditions.

Verbatim abstract via PubMed 38540265 ↗